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Abstract
Gut microbes play important roles in regulating fat storage and metabolism. Rhizoma coptidis (RC) and its main active
compound, berberine, have either antimicrobial or anti-obesity activities. In the present study, we hypothesize that RC
exerts anti-obesity effects that are likely mediated by mechanisms of regulating gut microbes and berberine may be a key
compound of RC. Gut microbes and glucose and lipid metabolism in high-fat diet-fed C57BL/6J (HFD) mice in vivo are
investigated after RC and berberine treatments. The results show that RC (200 mg/kg) and berberine (200 mg/kg)
significantly lower both body and visceral adipose weights, and reduce blood glucose and lipid levels, and decrease
degradation of dietary polysaccharides in HFD mice. Both RC and berberine significantly reduce the proportions of fecal
Firmicutes and Bacteroidetes to total bacteria in HFD mice. In the trial ex vivo, both RC and berberine significantly inhibit
the growth of gut bacteria under aerobic and anaerobic conditions. In in vitro trials, both RC and berberine significantly
inhibit the growth of Lactobacillus (a classical type of Firmicutes) under anaerobic conditions. Furthermore, both RC and
berberine significantly increase fasting-induced adipose factor (Fiaf, a key protein negatively regulated by intestinal
microbes) expressions in either intestinal or visceral adipose tissues. Both RC and berberine significantly increase mRNA
expressions of AMPK, PGC1a, UCP2, CPT1a, and Hadhb related to mitochondrial energy metabolism, which may be driven
by increased Fiaf expression. These results firstly suggest that antimicrobial activities of RC and berberine may result in
decreasing degradation of dietary polysaccharides, lowering potential calorie intake, and then systemically activating Fiaf
protein and related gene expressions of mitochondrial energy metabolism in visceral adipose tissues. Taken together, these
action mechanisms may contribute to significant anti-obesity effects. Findings in the present study also indicate that
pharmacological regulation on gut microbes can develop an anti-obesity strategy.
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Introduction
Obesity has emerged worldwide since 1999 with a stable and
increasing tendency [1]. Obesity has profound impacts on
cardiovascular diseases. However, the prevention and treatment
of obesity remain significant challenges to medicinal scientists [2].
Obesity is derived from interactions of genetic and environmental
factors. Gut microbes play important roles in regulating fat storage
and metabolism [3].Although gut microbes are potential targets, no
appropriate drugs that target them have been developed thus far.
In traditional Chinese medicine, Rhizoma coptidis (RC, contain-
ing the active component berberine) is mostly used to clear heat,
purge sthenic fire, and eliminate toxic materials. RC and
berberine affect a variety of organisms, including bacteria, viruses,
and fungi [4–9]. In China, RC and berberine are mostly used as
drugs against intestinal infections [10]. RC and berberine have
significant effects in lowering blood glucose, lipid, and body weight
[11–15], and most studies indicate that RC and berberine directly
exert metabolism-regulating effects [11–13]. However, berberine
has low bioavailability after oral administration. Actually, it may
be very difficult to reach effective concentrations in metabolism-
regulating tissues in vivo, eg. visceral adipose tissues. Pharmaco-
kinetics studies show that the maximum plasma concentrations of
berberine vary from 0.01 to 0.40 mg/ml and even are lower than
0.01 mg/ml after oral administration [16]. The actual concentra-
tions of berberine in visceral adipose tissues may be far lower than
that in blood since these tissues have limited blood flow. However,
studies in vitro indicate that the effective concentrations of
berberine vary from 1 to 10 mg/ml [17,18]. So, there are concerns
about whether berberine can completely exert the effects after its
limited intestinal absorption. It seems to be more reasonable to
conclude that effects of berberine or RC contained berberine
might mediate by targeting on gut tissues.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24520Taken together, in the present study, we hypothesize that RC
exerts anti-obesity effects partly mediated by mechanisms of
regulating gut microbes, and berberine may be a key active
compound of RC that is responsible for these effects. The effects of
RC and berberine in gut microbes, obesity, and their relationships
are investigated in high-fat diet-fed C57BL/6J (HFD) mice.
Results
Effect of RC and berberine on body weight, visceral
adipose tissues, and metabolic parameters in high-fat
diet-fed C57BL/6J mice
Compared with normal chow diet-fed controls,HFD mice showed
significant increases in body and visceral adipose weights (Fig. 1).
However, RC and berberine significantly inhibited increases in body
and fat weights in HFD mice. In trials of metabolic cages, HFD mice
showed increased calorie intakes compared with normal controls
(Table 1), which may be why HFD showed increases in body weight
gain. RC and berberine did not significantly affect food intake, which
suggests that they exert anti-obesity effects that are completely
independent of food intake. In addition, HFD mice increased water
intake and urine excretion, but decreased fecal excretion compared
with normal controls. RC and berberine significantly decreased water
intake and showed a decreased tendency to excrete urine, although
not in a significant manner. Furthermore, HFD mice showed
decreased fecal excretion compared with normal controls, but RC
and berberine normalized this decrease.
Effect of RC and berberine on blood glucose, lipid, and
fecal lipid and polysaccharide levels in high-fat diet-fed
C57BL/6J mice
HFD mice showed significant increases in blood glucose and
total cholesterol but had no significant change in serum trigly-
cerides compared withnormalcontrols(Table1).RCandberberine
significantly inhibited increases in blood glucose and total
cholesterol levels in HFD mice. In addition, RC significantly
lowered serum triglycerides in HFD mice, whereas berberine did
not. For fecal lipid assays, HFD mice showed significant increases in
fecal triglycerides and total cholesterol levels compared with normal
controls. RC and berberine significantly decreased fecal cholesterol
concentrations and showed decreasing tendencies of fecal triglyc-
erides but not in a significant manner. This suggests that both RC
and berberine have anti-obesity activities or lipid-lowering effects,
Figure 1. Effects of RC and berberine on (a) body weight and (b) visceral adipose tissue weight in HFD mice. ‘‘Normal’’, normal chow
diet-fed mice; ‘‘HFD’’, high-fat diet-fed control mice; ‘‘berberine’’, berberine-treated HFD mice; ‘‘RC’’, Rhizoma coptidis-treated HFD mice. Data were
expressed as Mean6S.D. (n=10), *P,0.05, **P,0.01 vs. HFD controls.
doi:10.1371/journal.pone.0024520.g001
Table 1. Effects of RC and berberine on blood biochemical
assay parameters, metabolic cage trials, and fecal lipid and
polysaccharide evaluations in HFD mice.
Normal HFD Berberine RC
Blood glucose
(mmol/L)
7.160.7* 8.260.8 6.561.5* 5.861.2**
Serum total
cholesterol (mg/dl)
98.768.0** 120.968.7 100.3615.7* 96.6611.8*
serum triglycerides
(mmol/L)
0.9760.21 1.0560.06 1.0260.43 0.5760.08**
Diet intake
(Kcal/mouse)
11.260.59** 13.161.49 11.962.00 13.762.13
Water intake
(ml/mouse)
3.061.09** 4.360.54 3.960.29* 3.760.27**
Fecal excretion
(g/mouse)
1.660.39** 0.960.23 1.660.29** 1.360.13**
Urine excretion
(ml/mouse)
1.360.54* 2.060.67 1.860.40 1.760.33
Fecal triglycerides
(mg/g)
2.1660.41** 3.4560.88 2.9060.69 2.8660.53
Fecal cholesterol
(mg/g)
3.8161.09** 8.3761.71 6.6261.29* 6.5361.40*
Fecal polysaccharides
(mg/g)
16.467.2 18.563.1 35.366.3** 33.462.4**
‘‘Normal’’, normal chow diet-fed mice; ‘‘HFD’’, high-fat diet-fed control mice;
‘‘berberine’’, berberine-treated HFD mice; ‘‘RC’’, Rhizoma coptidis-treated HFD
mice. Data were expressed as Mean6S.D. (n=10),
*P,0.05,
**P,0.01 vs. HFD controls.
doi:10.1371/journal.pone.0024520.t001
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caloric content of fecal lipid excretion was less than 1% of the total
dietary caloric intake and negligible in all groups. It can be
concluded that both RC and berberine may exert anti-obesity
activities or lipid-lowering effects through enhanced energy
expenditure. In addition, HFD mice did not show significant
change of fecal polysaccharide content compared with normal
controls. Interestingly, both RC and berberine significantly
increased the fecal polysaccharide content. Therefore, RC and ber-
berine exert anti-obesity activities or lipid-lowering effects partly by
mechanisms of inhibiting degradation of dietary polysaccharides.
Effect of RC and berberine on 16SrRNA gene of
Bacteroidetes and Firmicutes in feces of high-fat diet-fed
C57BL/6J mice
Six mice from each group were randomly selected for the trials.
Gene expressions of 16SrRNA showed that there were no signi-
ficant differences in the ratios of fecal Firmicutes or Bacteroidetes
to total bacteria between HFD and normal mice, although the
ratio of Firmicutes to total bacteria showed increased tendencies in
HFD mice compared with normal controls (Fig. 2). RC and
berberine significantly inhibited the ratios of Firmicutes or
Bacteroidetes to total bacteria in the feces of HFD mice. RC
and berberine significantly reduced Bacteroidetes compared with
HFD controls by 81.8% and 87.4%, respectively, and Firmicutes
compared with HFD controls by 49.7% and 82.4%, respectively.
Effect of RC and berberine on growth of fecal bacteria ex
vivo under aerobic and anaerobic conditions
After 24–26 h of culture ex vivo, no significant differences in
fecal bacteria growth between HFD and normal mice were
observed under both aerobic and anaerobic conditions (Fig. 3).
However, RC and berberine significantly inhibited the growth of
fecal bacteria under both aerobic and anaerobic conditions.
Effect of RC and berberine on growth of Lactobacillus sp.
under anaerobic conditions in vitro
After 24–26 h of culture in vitro, RC at a minimum
concentration of 0.313 mg/mL and berberine at a minimum
concentration of 0.078 mg/mL significantly inhibited the growth of
Lactobacillus sp., a classic type of Firmicutes, by more than 50%
(Fig. 4).In addition,high concentrationsof RC and berberine (more
than 0.5 mg/mL) interfered with the assay of bacteria turbidity at
620 nm. Using Excel software, the IC50 values of RC and berberine
were calculated to be 0.199 and 0.044 mg/mL, respectively. In the
intestinal tractsofmice,the inhibition concentrationsmaybefarless
than the actual concentrations because mice were orally adminis-
trated with 200 mg/kg RC or berberine.
Effect of RC and berberine on Fiaf protein expressions in
intestinal and visceral adipose tissues
Fiaf expression was significantly decreased in visceral adi-
pose tissues of HFD mice compared with normal controls (Fig. 5).
However, Fiaf expression in gut tissues showed decreasing
Figure 2. Effects of RC and berberine on 16SrRNA gene relative expressions of (a) Bacteroides/total bacteria and (b) Firmicutes/
total bacteria in feces of HFD mice. ‘‘Normal’’, normal chow diet-fed mice; ‘‘HFD’’, high-fat diet-fed control mice; ‘‘berberine’’, berberine-treated
HFD mice; ‘‘RC’’, Rhizoma coptidis-treated HFD mice. Data were expressed as Mean6S.D. (n=6), *P,0.05, **P,0.01 vs. HFD controls.
doi:10.1371/journal.pone.0024520.g002
Figure 3. Effects of RC and berberine on growth of fecal
bacteria ex vivo under (a) aerobic and (b) anaerobic condi-
tions. ‘‘Normal’’, normal chow diet-fed mice; ‘‘HFD’’, high-fat diet-fed
control mice; ‘‘Berberine’’, Berberine-treated HFD mice; ‘‘RC’’, Rhizoma
Coptidis-treated HFD mice (n=6).
doi:10.1371/journal.pone.0024520.g003
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no significant change. A greater number of samples may be
required in future trials. Despite this limitation, both RC and
berberine significantly increased the expression of Fiaf in either
visceral adipose tissues or intestines.
Effect of RC and berberine on gene expressions in
visceral adipose tissues and livers
For visceral adipose tissues, mRNA expressions of PGC1a,
Hadhb, CPT1a, and Acaal were significantly decreased in HFD
mice compared with normal controls (Fig. 6a). Both RC and
berberine significantly increased mRNA expressions of AMPK1a,
PGC1a, UCP2, Hadhb, and CPT1a in HFD mice, suggesting that
RC and berberine activate energy metabolism. In the present
study, RC and berberine significantly activated the expressions of
key genes responsible for adipogenesis, such as PPARc2, FABP4,
and LPL. In addition, RC significantly increased Acaa1
expression, whereas berberine increased the expressions of Acox
and Ehhadh.
For liver tissues, mRNA expressions of PGC1a and Hadhb were
significantly decreased in HFD mice compared with normal
controls (Fig. 6b). RC significantly increased mRNA expressions of
UCP2, Hadhb, Acaal, Acox1, and Ehhadh, whereas berberine
significantly increased mRNA expressions of AMPK1a and
UCP2. In the present study, both RC and berberine significantly
activated the expression of key genes mediating adipogenesis, such
as PPARc2 and LPL. RC and berberine significantly increased
LPL expression by more than 10-fold in either visceral adipose or
liver tissues.
Discussion
Although normal chow diets induce obesity in obesity-prone
animals [19], a high-fat diet remains an important catalyst for the
induction of animal models with visceral obesity [20–22] in a short
term. A high-fat diet increases blood glucose and total cholesterol
levels, although it has no significant influence in serum
triglycerides as previously reported in C57BL/6 [21], NIH [22],
and ICR [23] mice. High-fat diet-fed obesity may be associated
with increase of calorie intake in C57BL/6 mouse model. RC and
berberine significantly normalized blood glucose and lipid levels
and reduced body weight gain and visceral obesity in HFD mice,
suggesting that both may be directly used to treat diet-
induced obesity. RC and berberine at appropriate dosages did
not significantly affect dietary calorie intake and did not inhibit
intestinal lipid absorption in the present study. Therefore,
additional anti-obesity mechanisms should be further elucidated
for both RC and berberine. Interestingly, both RC and berberine
significantly inhibited the degradation of dietary polysaccharides,
Figure 4. Effects of (a) berberine and (b) RC on the growth of Lactobacillus sp. under anaerobic conditions in vitro.
doi:10.1371/journal.pone.0024520.g004
Figure 5. Effects of RC and berberine on Fiaf protein
expressions in intestinal and adipocyte tissues. ‘‘Normal’’, normal
chow diet-fed mice; ‘‘HFD’’, high-fat diet-fed control mice; ‘‘berberine’’,
berberine-treated HFD mice; ‘‘RC’’, Rhizoma coptidis-treated HFD mice.
Data were expressed as Mean6S.D. (n=6), *P,0.05, **P,0.01 vs. HFD
controls.
doi:10.1371/journal.pone.0024520.g005
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in guts or de novo lipogenesis.
Gut microbes, as environmental factors, regulate fat storage and
metabolism [3,24]. Gut microbiota in adult germ-free mice produce
rapid increases in body fat content, which may be associated with the
acceleration of the processing of dietary polysaccharides and
induction of de novo lipogenesis. As well, gut microbiota in adult
germ-free mice may be associated withdecreased fatty acid oxidation.
Relative proportions of microbial communities also affect body
weight gain. Bacteroidetes and Firmicutes are two main communities
that affect energy metabolism homeostasis [25]. Some studies suggest
that obese animals or humans have more Firmicutes and less
Bacteroidetes than lean controls [26,27], and, therefore, novel
therapeutic agents using probiotics, antibiotics, and/or prebiotics to
treat obesity should be developed [25]. However, limited data
support this idea.
Rhizoma coptidis, a traditional Chinese medicine, together with its
active compound, berberine, has known effects against a variety of
organisms. In the trial ex vivo, both RC and berberine inhibited
the growth of either aerobic or anaerobic microbes. Furthermore,
RC and berberine decreased the number of Firmicutes and
lowered that of Bacteroidetes in the feces of HFD mice.
Lactobacillus sp. is a classical type of Firmicutes. In the in vitro
trials, specific dosages of RC and berberine significantly inhibited
the growth of Lactobacillus, with both RC and berberine exerting
hypoglycemic or hypolipidemic and body-regulating effects. In our
preliminary trial, metronidazole, an antimicrobial drug against
anaerobic bacteria, also significantly inhibited body weight gain
(data not shown). Therefore, both RC and berberine exert anti-
obesity effects by inhibiting fecal microbes. This inhibition effect
might be associated with the increase in fecal polysaccharide
content and decrease in intestinal calorie intake and de novo
lipogenesis as prescribed above.
Increased expression of Fiaf in germ-free mice was selectively
suppressed in the intestinal epithelium after exposure to gut
microbes [24]. Conversely, RC and berberine significantly
promoted the expression of Fiaf in intestinal and adipose tissues in
HFD mice, which may be associated with their antimicrobial
activities. HFD may affect the proportion of communities of
intestinal microbes (although not in a significant manner) and
regulate the expression of Fiaf. In the present study, Fiaf expression
in visceral adipose tissues of HFD mice was significantly decreased
compared withnormal controls. Increased Fiafexpression enhances
energy metabolism by activating AMPK and up-regulating PGC1a
Figure 6. Effects of RC and berberine on gene expressions in visceral adipose tissues and livers. ‘‘Normal’’, normal chow diet-fed mice;
‘‘HFD’’, high-fat diet-fed control mice; ‘‘berberine’’, berberine-treated HFD mice; ‘‘RC’’, Rhizoma coptidis-treated HFD mice. Data were expressed as
Mean6S.D. (n=6), *P,0.05, **P,0.01 vs. HFD controls.
doi:10.1371/journal.pone.0024520.g006
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energy metabolism by activating AMPK and PGC1a pathways.
Activation of AMPK enhances oxidative metabolism and mito-
chondrial biogenesis, and then switches on catabolic pathways that
produce ATP [28]. PGC1a controls many aspects of oxidative
metabolism including mitochondrial biogenesis and respiration
[29].
Upregulation of PGC1a or activation of AMPK promotes
mitochondrial energy or lipid oxidation metabolism and causes wide
and coordinated changes in the related genes. UCP2, CPT1a,a n d
Hadhb are marker genes responsible for energy or mitochondrial fat
oxidation metabolism. UCP2 is widely expressed in tissues and likely
associated with the control of reactive oxygen species production by
mitochondria, regulation of ATP synthesis, and fatty acid oxidation
[30]. CPT1a is the rate-limiting enzyme carnitine palmitoyl-
transferase, which regulates fatty acid oxidation [31] and is regulated
by PGC1a. Hadhb is the mitochondrial trifunctional protein with a
multienzyme complex of the fatty acid b-oxidation cycle [32]. In the
present study, RC and berberine significantly promoted mRNA
expressionsofthese energy metabolismgenesinHFDmice,suggesting
that both may activate mitochondrial energy or fat oxidation
metabolism. This increase is mainly present in visceral adipose tissues,
indicating that both RC and berberine directly activate mitochondrial
energy metabolism in visceral adipose tissues.
Acox1, Acaal, and Ehhadh are key genes responsible for
peroxisomal b-oxidation. Peroxisomal b-oxidation plays an
important role in fat metabolism [20]. In livers or visceral adipose
tissues, RC or berberine slightly or moderately increased these or
part of these gene expressions responsible for peroxisomal b-
oxidation. The increase was not as highly expressed as observed in
mitochondrial genes, suggesting that RC or berberine mainly
enhance energy metabolism through the mitochondrial, not the
peroxisomal pathway.
RC and berberine increased the expressions of mRNAs
responsible for adipogenesis (PPARc2, FABP4, and LPL), which
may be associated with a compensatory response to increased
mitochondrial energy metabolism, because both RC and berber-
ine actually lowered body weight and visceral fat accumulation.
PPARc2 and LPL play important roles in adipocyte differentiation
[33] and fatty acid intake [34], respectively. Activation of PPARc2
and LPL increases insulin sensitivity [35] and lowers serum
triglycerides [34], respectively. In previous trials in vivo, berberine
significantly increased LPL activities [36]. Taken together, these
may explain why RC and berberine have anti-hyperglycemic,
anti-hyperlipidemic, and anti-obesity effects.
In the present study, the effects of RC were comparable to
berberine at a similar dose (200 mg/kg). Therefore, berberine is a
key active compound of RC. In addition, RC only contained
24.2% berberine but the effects of RC were comparable to those of
berberine at a similar dose (200 mg/kg). This finding suggests that
other compounds of RC may exert an effect similar to or stronger
than that of berberine. However, this may require further studies
in the future. The preparation of RC is very simple and low-cost
compared with berberine. No untoward effects of RC were found
in the animals during the testing period. Therefore, RC shows
better application potential in patients with diet-induced obesity.
In conclusion, in the present study, we first showed that both RC
and berberine exert anti-hyperglycemic, antihyperlipidemic, and
anti-obesity effects likely mediated by inhibiting gut microbes. The
antimicrobial activities of RC and berberine may result in
decreasing degradation of dietary polysaccharides (it seemed to
haveno influenceon intestinallipid absorption),lowering additional
calorie intake (from dietary polysaccharides) and de novo lipogenesis,
and then systemically increasing expression of Fiaf protein and
promoting expressions of energy metabolism genes (AMPK1a,
PGC1a, UCP2, CPT1a, and Hadhb) in visceral adipose tissues.
Taken together, these activities may contribute to significant anti-
obesity effects. Berberine may be a key active compound of RC that
is responsible for these effects. In this study, we firstly show the
evidence that pharmacological regulation of gut microbes by RC
and berberine can develop an anti-obesity strategy. Future studies
should focus on developing more appropriate drugs with antimi-
crobial activities to control diet-induced obesity.
Materials and Methods
Diets and animals
Four-week old male C57BL/6J mice [SPF grade, Certified
No. SCXK (Hu) 2007-0005] were obtained from Shanghai Slac
Laboratory Animal, Co., Ltd. (Shanghai, China). Animals were
kept in an environmentally controlled breeding room (tempera-
ture: 2062uC, humidity: 6065%, 12 h dark/light cycle). They
were fed standard laboratory chow with water ad libitum and fasted
from 9:00 am to 3:00 pm before the experiments. The study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of Institutional
Animal Care and Use Committee of Tsinghua University. The
protocol was approved by the Animal Welfare and Ethics
Committee of Tsinghua University, China (No. 2010-XWD-AE).
All surgeries were performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize suffering. Both
normal chow and high-fat diets were purchased from Shanghai
Slac Laboratory Animal Co., Ltd. Normal chow diets contained
20.5% crude protein, 4.62% crude fat, 52.5% nitrogen-free
extract, and 4.35% crude fibers (total calories 3.45 Kcal/g, 12%
calories in fat). High-fat diets contained 18.8% crude protein,
16.2% crude fat, 45.2% nitrogen-free extract, and 3.98% crude
fibers (total calories 3.79 Kcal/g, 38% calories in fat).
Preparation of ethanol extracts of RC
Ethanol extracts of RC were prepared by Dr. Qixin Yan of
Neptunus Bio-Engineering Co., Ltd., Shenzhen, China. In brief,
611 g dried RC powder were refluxed with 5 L of 75% ethanol for
3 h. The extracted solution was then filtered with 3–5 mm thin
cotton, and the filtered solution was dried by water bath at 90uC.
The residues were dried by vacuum dryer at 50uC overnight. The
yield of the ethanolic extracts of RC was 17.10% (g/g). The HPLC
fingerprint of the ethanol extracts of RC is shown in Fig. 7 to
guarantee stable quality control. Berberine, a potential active
compound of the ethanol extracts of RC, was found to have a
content of about 24.2%.
Experimental protocol
Mice were divided into four groups: common chow diet-fed
normal animals (Normal), high-fat diet-fed controls (HFD),
berberine (200 mg/kg)-treated high-fat diet-fed animals, and RC
(200 mg/kg)-treated high-fat diet-fed animals. RC or berberine
(Guandong Huanan Pharmacy, Ltd., China) was freshly suspended
in distilled water and orally administered to the mice by gavage.
Identical volumes of distilled water were given to normal and HFD
controls. Body weight was monitored once a week. The dietary
intake, water intake, urine volume, and fecal weight of each mouse
were recorded while in the metabolic cage for 24 h, once a week.
Total calorie intake was calculated according to dietary calorie
intake, and expressed as Kcal/mice/day. Freshly collected feces
were used for lipid and bacteria number assays. After six weeks of
normal and high-fat diet feeding, the animals were weighed and
anesthetized by intraperitoneal injection of pentobarbital at a dose
Drugs, Gut Microbes and Anti-Obesity Strategy
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six-week treatment. Serum was isolated by centrifugation at 1500 g
at 4uC for 10 min and stored at 280uC until it was used for blood
biochemical assays. Following blood collection, the anesthetized
mice were sacrificed by cervical dislocation. Visceral adipose tissues
(perigonadal fat, the main part of the internal white adipose tissues),
livers, and intestinal tracts were removed from the animals. Visceral
adipose tissues were immediately weighed after removal from the
animal. The samples were instantly frozen in liquid nitrogen and
then stored at 280uC until they were used for biochemical analysis.
Biochemical analysis
Blood glucose, total cholesterol, and triglycerides were assayed
using commercial kits (BioSino Bio-Technology and Science, Inc.,
Beijing, China). Blood glucose was estimated by the glucose
oxidase method [37]. Total cholesterol was estimated by the
method of Allain et al. [38]. Triglyceride levels were determined
by the enzymatic method [39]. Fecal lipid assay was conducted
according to a previous protocol [19]. Fecal polysaccharide assay
was according to anthrone-reagent method [40].
16SrRNA gene expression analysis of fecal Firmicutes and
Bacteroidetes in mice by Real-time PCR
The 16SrRNA analysis of Firmicutes, Bacteroidetes, and total
bacteria in feces was performed in accordance with a previous method
[41] with slight modifications. Briefly, about 0.1–0.2 mg fresh fecal
samples from the intestines of different groups of mice were collected
and suspended with 1 mL PBS in a 1.5-mL Eppendorf tube. The fecal
suspension was centrifuged at 500–1000 rpm for 5 min. The collected
supernatants were further centrifuged at 10,000 rpm for 5 min. The
deposit containing fecal bacteria was used to extract gnomic DNA.
Genomic DNA was extracted with a TaKaRa minibest bacterial
genomic DNA extraction kit (TaKaRa, Dalian, China). The DNA
samples were then subjected to DNA quantitative analysis. Clostridium
perfringens (CICC No. 22949, China Center of Industrial Culture
Collection, China) was selected as standard strain for quantitative
assays of the relative content of 16SrRNA gene of Firmicutes and total
bacteria. Bacteroides thetaiotaomicron (ATCCH 29741
TM)s e r v e da s
standard strain for quantitative assays of the relative content of
16SrRNA gene of Bacteroidetes. The primers of Firmicutes,
Bacteroidetes, and total bacteria were set as shown in Table 2. Data
of relative expression contents were calculated according to the
following steps and formulas:
I) lgC~KCtzb
II)
Bact
Allb
(%)~ 10 KBact|CtBact{KAllb|CtAllb ðÞ z bBact{bAllb ðÞ
hi
|100%
III)
Firm
Allb
(%)~ 10 KFirm|CtFirm{KAllb|CtAllb ðÞ z bFirm{bAllb ðÞ
hi
|100%
IV) 16SrRNA relative expression of
Bact
Allb
in each group
~10
KBact|CtBact{KAllb|CtAllb ðÞ Testedgroup
{ KBact|CtBact{KAllb|CtAllb ðÞ HFDcontrol
"#
V) 16SrRNA relative expression of
Firm
Allb
in each group
~10
KFirm|CtFirm{KAllb|CtAllb ðÞ Testedgroup
{ KFirm|CtFirm{KAllb|CtAllb ðÞ HFDcontrol
"#
where C is the DNA copy number, KBact or KFirm is the slope of
the linear regression and correlation formula (lgC=KCt+b)
from the standard curves of Bacteroidetes or Firmicutes
controls, respectively, and Ct refers to Ct values of from the
q-PCR of Bacteroidetes (Bact), Firmicutes (Firm), and total
bacteria (Allb).
Figure 7. HPLC fingerprint of ethanol extracts of Rhizoma coptidis (RC). Chromatogram conditions: Kromasil C18 column (5 mm,
4.6 mm6250 mm), column temperature, 30uC; mobile phase, acetonitrile: H2O (0.05 M KH2PO4, pH 3.0)=30:70 (v/v); elution rate, 1 ml/min; detector
wavelength, 345 nm. Peak ‘‘1’’, berberine (content, 24.2%).
doi:10.1371/journal.pone.0024520.g007
Drugs, Gut Microbes and Anti-Obesity Strategy
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24520Fecal bacteria culture ex vivo under anaerobic or aerobic
condition
As previously described, collected fecal bacteria were
suspended in PBS and normalized according to fecal weight.
First, 5 m: fecal bacteria stock solution (OD620 nm 0.2–0.4) was
added to 200 mL MRS Broth culture (Qingdao Hope Bio-
Technology Co., Ltd, China) and diluted with 200 mLM R S
Broth culture 2
1–10 times in a 96-well plate. For anaerobic
cultures, as 96-well plate containing the bacterial solution at
different dilution concentrations was placed in a Pack-Rectan-
gular Jar 2.5 Liter with one AnaeroPack sachet freshly opened
(AnaeroPack System, Mitsubishi Gas Chemical Co., Inc.,
Japan). The Pack-Rectangular Jar 2.5 Liter was then placed in
37uC controlled incubator. After 24–36 h of culture, the culture
solution containing bacteria was slightly re-suspended. Finally,
the wells were assayed at 620 nm for bacteria turbidity. For
aerobic culture, the 96-well plate was directly placed in a 37uC
controlled incubator. The other procedures were similar to
those of the anaerobic culture.
Lactobacillus culture in vitro
First, 1 mL Lactobacillus (No. 21024, CICC) stock solution
(OD620 nm 0.2–0.4) was added to 200 mL MRS broth culture
in a 96-well plate. At the same time, RC at final concentrations of
80, 40, 20, 10, 5, 2.5, 1.25, 0.625, 0.313, 0.156, and 0 mg/mL or
berberine at final concentrations of 40, 20, 10, 5, 2.5, 1.25, 0.625,
0.313, 0.156, 0.078, and 0 mg/mL was added to 200 mL MRS
broth culture. Afterwards, the 96-well plate was placed in a Pack-
Rectangular Jar 2.5 Liter with one freshly opened AnaeroPack
sachet. The Pack-Rectangular Jar 2.5 Liter was then placed in a
controlled incubator set to 37uC. After 24–36 h of culture, the
culture solution containing bacteria was slightly re-suspended.
Finally, the wells were assayed at 620 nm for bacteria turbidity.
Inhibition rate (%) was calculated according to the formula:
Inhibition Rate(%)~
OD620nm(Control){OD620nm(Drug)
  
OD620nm(Control)
|100%
Table 2. Primers for Bacteroidetes, Firmicutes, and total
bacteria.
Primers (59 to 39) Size(bp)
Bacteroidetes Forward GGARCATGTGGTTTAATTCGATGAT 126
Reverse AGCTGACGACAACCATGCAG
Firmicutes Forward GGAGYATGTGGTTTAATTCGAAGCA 126
Reverse AGCTGACGACAACCATGCAC
Total bacteria Forward ACTCCTACGGGAGGCAGCAG 200
Reverse ATTACCGCGGCTGCTGG
doi:10.1371/journal.pone.0024520.t002
Table 3. Primers for energy metabolism genes.
Gene names NCBI Accession No. Primers (59 to 39) Sizes (bp)
PPARc2 NM_011146.3 Forward: TTTCAAGGGTGCCAGTTT 152
Reverse: GAGGCCAGCATCGTGTAG
FABP4 NM_024406.2 Forward: AAATCACCGCAGACGACA 138
Reverse: CACATTCCACCACCAGCT
LPL NM_008509.2 Forward: AACAATCTGGGCTATGA 262
Reverse: CCACCTCCGTGTAAATC
AMPKa1 NM_001013367.3 Forward: TTCAGGCACCCTCACATC 268
Reverse: GACCAAAGTCGGCTATCT
PGC1a NM_008904.2 Forward: ACAGCAAAAGCCACAAAG 259
Reverse: TAAGGTTCGCTCAATAGTC
UCP2 NM_011671.4 Forward: AATGTTGCCCGTAATGCC 299
Reverse: CCCAAGCGGAGAAAGGAA
CPT1a NM_013495.2 Forward: CGTGACGTTGGACGAATC 165
Reverse: TCTGCGTTTATGCCTATC
Acox1 NM_015729 Forward: CCGCCTATGCCTTCCACT 182
Reverse: ACCGCAAGCCATCCGACA
Ehhadh NM_023737.3 Forward: TGGACCATACGGTTAGAG 213
Reverse: CAATCCGATAGTGACAGC
Acaa1 NM_130864.3 Forward: GATGACCTCGGAGAATGTGG 188
Reverse: CCTGAGACACGGTGATGGT
Hadhb NM_145558 Forward: TGTCAGGCACTTCGTAT 153
Reverse: TAGCCACATTGCTTGTT
GAPDH NM_008084 Forward: TCTCCTGCGACTTCAACA 178
Reverse: TGGTCCAGGGTTTCTTACT
doi:10.1371/journal.pone.0024520.t003
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Freshly prepared visceral adipose tissues or small intestines
(n=6) were homogenated and lysed with NETN buffer (20 mM
Tris-HCl, pH 7.8, 1 mM EDTA, 50 mM sodium chloride, and
0.5% NP-40). Lysates were centrifuged at 12,000 rpm at 4uCf o r
2–10 min. Supernatants were collected and protein concentra-
tion was determined by a bicinchoninic acid protein assay kit
(Nanjing Jiancheng Biotech, China). Western blot analysis was
carried out according to the manufacturer’s protocol. Antibod-
ies against Fiaf and GAPDH (Santa Cruz Biotechnology, Inc.)
were used. Protein expression was visualized with horseradish
peroxidase-conjugated secondary antibodies (Amersham Biosci-
ences, USA; 1:2000) and enhanced chemiluminescence (KPL,
USA).
Real-time PCR analysis of mRNAs
Approximately 100 mg of visceral adipose tissues were removed
and immediately frozen in liquid nitrogen (n=6). Total RNA was
extracted using TRIZOL reagent (Invitrogen) according to
themanufacturer’s instructions. Reverse transcription was carried
out using PrimeScript
TM 1st Strand cDNA Synthesis Kit (Takara,
Dalian, China). The cDNA fragments were amplified using Taq
DNA Polymerase (Takara, Dalian, China) according to manufac-
turer’s instructions. Many key genes are responsible for adipogen-
esis and fat oxidation metabolism. For example, peroxisome
proliferators activate receptor gamma (PPARc), fatty acid binding
protein 4 (FABP4) and lipoprotein lipase (LPL) are key marker
genes for adipogenesis, and AMP-activated protein kinase
(AMPK), peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC1a), uncoupling protein 2 (UCP2), and
carnitine palmitoyl transferase 1-alpha (CPT1a) are key genes for
lipid oxidation or mitochondrial energy metabolism. As previously
described [20], there are three peroxisomal b-oxidation genes,
namely, acyl-CoA oxidase 1 palmitoyl (Acox1), enoyl-CoA
hydratase/3-hydroxyacyl–CoA dehydrogenase (Ehhadh), 3-oxoa-
cyl–CoA thiolase (Acaa1), and one mitochondrial b-oxidation
gene, hydroxyacyl-CoA dehydrogenase/3-ketoacyl–CoA thiolase/
enoyl-CoA hydratase (Hadhb, trifunctional protein, beta subunit).
In the present study, these genes were chosen for quantitative real-
time PCR (q-PCR), and primers were synthesized from Invitrogen
(Table 3). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as internal control for normalization. q-PCR analysis was
conducted by the method of SYBRH Green I dye according to the
protocol of the kit (Code No. DRR081S, Takara, Dalian, China)
in an ABI PRISM 7300 Real time PCR system (Applied
Biosystems, USA). The q-PCR analysis involved two steps: 1)
predenaturation of cDNA samples at 95uC for 30 s at the first
stage, and then 2) amplification of denatured cDNA samples by 40
cycles at 95uC for 5 s and then at 60uC for 31 s at the second
stage. Data were expressed as raw relative quantitation (2
2ddCt).
Statistical analysis
Data were expressed as Mean6S.D. Statistical analysis was
performed using ANOVA. Newman–Keuls comparisons were
used to determine the source of significant differences where
appropriate. P values less than 0.05 were considered statistically
significant.
Author Contributions
Conceived and designed the experiments: WX DG. Performed the
experiments: WX DG JL KC. Analyzed the data: YZ. Contributed
reagents/materials/analysis tools: WX DG YZ. Wrote the paper: WX.
References
1. Rokholm B, Baker JL, Sørensen TI (2010) The levelling off of the obesity
epidemic since the year 1999–a review of evidence and perspectives. Obes Rev
11: 835–846.
2. Powell TM, Khera A (2010) Therapeutic approaches to obesity. Curr Treat
Options Cardiovasc Med 12: 381–395.
3. Ba ¨ckhed F, Manchester JK, Semenkovich CF, Gordon JI (2007) Mechanisms
underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl
Acad Sci U S A104: 979–84.
4. Li ZX, Wang XH, Zhao JH, Yang JF, Wang X (2001) Studies on in vitro
antibacterial activity of Coptis chinensis against 252 strains inclinic with mueller-
hinton agar. Zhong Cao Yao 32: 337–339. [Article in Chinese].
5. Shi QM, Shen P, Chen LF, He YW (2003) Research of screening the anti-virus
herbs. Zhong Guo Dong Wu Bao Jian 9: 22–23. –29. [Article in Chinese].
6. Wang L, LV XL, Sun L, Shen YN, Liu WD (2008) Studies on antifungal activity
of extracts from six traditional Chinese medicines against Dermatophyte genus.
Zhong Guo Pi Fu Xing Bing Xue Zha Zhi 22: 498–500. [Article in Chinese].
7. Yan D, Jin C, Xiao XH, Dong XP (2008) Antimicrobial properties of berberines
alkaloids in Coptis chinensis Franch by microcalorimetry. J Biochem Biophys
Methods 70: 845–849.
8. Freile ML, Giannini F, Pucci G, Sturniolo A, Rodero L, et al. (2003)
Antimicrobial activity of aqueous extracts and of berberine isolated from
Berberis heterophylla. Fitoterapia 74: 702–705.
9. Iwazaki RS, Endo EH, Ueda-Nakamura T, Nakamura CV, Garcia LB, et al.
(2010) In vitro antifungal activity of the berberine and its synergism with
fluconazole. Antonie Van Leeuwenhoek 97: 201–205.
10. Wang XJ (2003) Pharmacological research and modern application of Coptis
chinensis. Zhong Guo Yao Shi 6: 370. [Article in Chinese].
11. Yin J, Zhang H, Ye J (2008) Traditional chinese medicine in treatment of
metabolic syndrome. Endocr Metab Immune Disord Drug Targets 8: 99–111.
12. Xie WD, Du LJ (2011) Diabetes is an inflammatory disease: evidences from
traditional Chinese Medicines. Diabetes Obes Metab 13: 289–301.
13. Xie WD, Zhao YN, Zhang YO (2011) Traditional Chinese medicines in
treatment of patients with type 2 diabetes mellitus. Evid Based Complement
Alternat Med. doi:10.1155/2011/726723.
14. Zhang Q, Xiao X, Feng K, Wang T, Li W, et al. (2011) Berberine Moderates
Glucose and Lipid Metabolism through Multipathway Mechanism. Evid Based
Complement Alternat Med. pii, 924851.
15. Hu Y, Davies GE (2010) Berberine inhibits adipogenesis in high-fat diet-induced
obesity mice. Fitoterapia 81: 358–366.
16. Li Y, You XF, Jiang JD (2008) Progress in pharmacokinetic researches of
berberine. Zhong Guo Xin Yao Zha Zhi 17: 733–738. [Article in Chinese].
17. Kong W, Wei J, Abidi P, Lin M, Inaba S, et al. (2004) Berberine is a novel
cholesterol-lowering drug working through a unique mechanism distinct from
statins. Nat Med 10: 1344–1351.
18. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a
natural plant product, activates AMP-activated protein kinase with beneficial
metabolic effects in diabetic and insulin-resistant states. Diabetes 55(8):
2256–2264.
19. Xie WD, Wang H, Zhang JF, Kung HF, Zhao YN, et al. (2010) Proteomic
profile of visceral adipose tissues between low-fat diet-fed obesity-resistant and
obesity-prone C57BL/6 mice. Mol Med Rep 3: 1047–1052.
20. Xie WD, Wang H, Zhang JF, Li JN, Yi C, et al. (2011) Enhanced peroxisomal
b-oxidation metabolism in visceral adipose tissues of high-fat diet-fed obesity-
resistant C57BL/6 mice. Exp Ther Med 2: 309–315.
21. Xie WD, Zhang YO, Wang NL, Du LJ, Zhou H, et al. (2008) Novel effects of
macrostemonoside A, a compound from Allium macrostemon Bung, on
hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed
C57BL/6 mice. Eur J Pharmacol 599: 159–165.
22. Xie WD, Nie Y, Du LJ, Zhang YO, Cai GP (2007) Preventive effects of
fenofibrate and vitamin C on the development of type 2 diabetes and its
complications in NIH mice induced by small-dose streptozotocin and lard.
Pharmacol Res 55: 392–399.
23. Xie WD, Du LJ (2005) High-cholesterol diets impair diabetic retention of
memory, but neither diabetic acquisition of memory nor pre-diabetic retention
of memory in alloxan-induced diabetic mice in a short term. Life Sci 77: 481–95.
24. Ba ¨ckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al. (2004) The gut
microbiota as an environmental factor that regulates fat storage. Proc Natl Acad
Sci U S A 101: 15718–15723.
25. Tennyson CA, Friedman G (2008) Microecology, obesity, and probiotics. Curr
Opin Endocrinol Diabetes Obes 15: 422–427.
26. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, et al.
(2008) Gut microbiota and its possible relationship with obesity. Mayo Clin Proc
83: 460–469.
27. Ley RE, Ba ¨ckhed F, Turnbaugh P, Lozupone CA, Knight RD, et al. (2005)
Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102:
11070–11075.
28. Canto ´ C, Auwerx J (2010) AMP-activated protein kinase and its downstream
transcriptional pathways. Cell Mol Life Sci 67: 3407–3423.
Drugs, Gut Microbes and Anti-Obesity Strategy
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e2452029. Spiegelman BM (2007) Transcriptional control of mitochondrial energy
metabolism through the PGC1 coactivators. Novartis Found Symp 287:
60–63; discussion 63–69.
30. Boss O, Hagen T, Lowell BB (2000) Uncoupling proteins 2 and 3: potential
regulators of mitochondrial energy metabolism. Diabetes 49: 143–156.
31. Jambor de Sousa UL, Koss MD, Fillies M, Gahl A, Scheeder MR, et al. (2005)
CPT1alpha over-expression increases long-chain fatty acid oxidation and
reduces cell viability with incremental palmitic acid concentration in 293T
cells. Biochem Biophys Res Commun 338: 757–761.
32. Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW (2003) Molecular
and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency
due to beta-subunit mutations. Hum Mutat 21: 598–607.
33. Siersbaek R, Nielsen R, Mandrup S (2010) PPARgamma in adipocyte
differentiation and metabolism–novel insights from genome-wide studies. FEBS
Lett 584: 3242–3249.
34. Fielding BA, Frayn KN (1998) Lipoprotein lipase and the disposition of dietary
fatty acids. Br J Nutr 80: 495–502.
35. Brunani A, Caumo A, Graci S, Castagna G, Viberti G, et al. (2008)
Rosiglitazone is more effective than metformin in improving fasting indexes of
glucose metabolism in severely obese, non-diabetic patients. Diabetes Obes
Metab 10: 460–467.
36. Zhou J, Zhou S (2010) Berberine regulates peroxisome proliferator-activated
receptors and positive transcription elongation factor b expression in diabetic
adipocytes. Eur J Pharmacol 649: 390–397.
37. Trinder P (1969) Determination of glucose in blood using glucose oxidase with
an alternative oxygen acceptor. Ann Clin Biochem 6: 24–27.
38. Allain CC, Poon LC, Chan CS, Richmond W, Fu PC (1974) Enzymatic
determination of total cholesterol. Clin Chem 20: 470–475.
39. Fossati P, Prencipe L (1982) Serum triglycerides determined colorimetrically
with an enzyme that produce hydrogen peroxide. Clin Chem 28: 2077–2080.
40. Roe JH, Dailey RE (1966) Determination of glycogen with the anthrone reagent.
Anal Biochem 15: 245–250.
41. Guo X, Xia X, Tang R, Zhou J, Zhao H, et al. (2008) Development of a real-
time PCR method for Firmicutes and Bacteroidetes in faeces and its application
to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 47:
367–373.
Drugs, Gut Microbes and Anti-Obesity Strategy
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24520